24/7 Market News Snapshot 15 August, 2025 – Precigen, Inc. Common Stock (NASDAQ:PGEN)

August 15, 2025

DENVER, Colo., 15 August, 2025 (www.247marketnews.com) – (NASDAQ:PGEN) are discussed in this article.
Precigen, Inc. has recently achieved a significant milestone with the FDA’s approval of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP), the first-ever therapy specifically targeting this rare and challenging condition affecting adults. Priced at $3.278, Precigen’s stock surged by an impressive 77.19% in pre-market trading, reflecting heightened investor interest and optimism surrounding this breakthrough. With a trading volume of 5.06 million shares, the market response underscores the positive outlook for the biotechnology firm.

PAPZIMEOS employs a novel, non-replicating adenoviral vector-based immunotherapy designed to enhance the immune response against papilloma cells associated with human papillomavirus (HPV) types 6 and 11, the primary cause of RRP. This innovative treatment not only addresses the underlying viral infection but is also anticipated to drastically reduce the frequency of surgical interventions often required in traditional management approaches. Data from pivotal trials demonstrated that 51% of participants reached a Complete Response, suggesting a considerable impact on patient quality of life.

Dr. Helen Sabzevari, President and CEO of Precigen, emphasized the import of this approval as a transformative development for adult patients who have faced prolonged challenges with RRP. “We are committed to bringing PAPZIMEOS to the RRP community, offering a viable therapeutic option that moves beyond repetitive surgeries,” she stated.

To facilitate patient access, Precigen is launching a comprehensive support program and plans to hold a conference call to outline further steps following this promising approval. The company’s achievements signal a forward-thinking approach and bolster its position as a leader in innovative healthcare solutions, marking the beginning of a new chapter for those managing RRP in the United States.

Related news for (PGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.